on behalf of the founders of organon, we are happy to be here.ast of thousands and we cannot be happier or more proud to launch organon today. we are going to be focused on women's health. this is a business that is comprised of established brands, and then women's health products in terms of fertility and contraception. we do see an op -- we do see an opportunity to go forward. when you start to look at the women's health sector we have to open the aperture beyond reproductive health and focus on those areas that are unique to women are disproportionately affect women. we made a recent acquisition with regards to olivia health to treat postpartum hemorrhage, a leading cause of mortality for women in childbirth. this is a fantastic asset and a fantastic device. we see opportunities in that space because we believe valuation is responsible, it is a good period of time to get in, and it has never been a time to launch a company like organon. alix: give us a sense of the timing and size of more deals you will be making. kevin: the thing to keep in m

organon a women's health company spun off from merck is joining in the trend we have kevin ali, the ceo thank you for joining us your first time with us. of course having just spun off from merck june 3rd. tell bus the combination of assets that you took from merck. you have got women's health, biosimilars and something you are calling established brands, sort of older medicines that didn't make sense for merck. tell us why they make sense together for roganon. >> great to be with you. on behalf of the 9,000 founders of organon, we are celebrating two weeks since our bell ringing ceremony at the new york stock exchange worry going hit the ground running. it is a women's health focused company. they are significant needs out there. we have a vibrant reproductive health business and contraceptives and fertility we have an opportunity to be an advocate for women's health assets yesterday we closed on our first deal, the lydia health acquisition to solve the issues around post partum hemorrhage one of the leading causes of death in women following child birth. we have biosimilars business c